Post-intervention vessel remodeling

Gene Therapy

Volumn 9, Issue 22, 2002, Pages 1487-1491

  Rutanen, J ^a   Puhakka, H ^a   Yla Herttula S ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Artery; Intimal hyperplasia; Neointima; Stenosis; Vein graft

Indexed keywords

APROTININ; FAS LIGAND; GELATINASE A; GELATINASE B; HOMEODOMAIN PROTEIN; HYBRID PROTEIN; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; NITRIC OXIDE SYNTHASE; PLASMID DNA; PLATELET DERIVED GROWTH FACTOR; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; RAS PROTEIN; RHO KINASE; SCATTER FACTOR; SUPEROXIDE DISMUTASE; THROMBOCYTE ACTIVATING FACTOR; THYMIDINE KINASE; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR E2F; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; UTEROGLOBIN; VASCULOTROPIN; VASCULOTROPIN C; VIRUS VECTOR;

BLOOD VESSEL INJURY; BLOOD VESSEL OCCLUSION; BYPASS SURGERY; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DRUG EFFICACY; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; GRAFT FAILURE; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER; SURGICAL TECHNIQUE; TRANSLUMINAL CORONARY ANGIOPLASTY; VEIN GRAFT; VEIN OCCLUSION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CORONARY DISEASE; CORONARY RESTENOSIS; ENDOTHELIAL GROWTH FACTORS; GENE THERAPY; GRAFT OCCLUSION, VASCULAR; HUMANS; HYPERPLASIA; MODELS, ANIMAL; MYOCARDIAL REVASCULARIZATION; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-MYC; TRANSDUCTION, GENETIC; TUNICA INTIMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0036857745     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301866     Document Type: Review

References (56)

1. Laitinen M et al. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum Gene Ther 2000; 11: 263-270.
2. Hiltunen MO, Turunen MP, Ylä-Herttuala S. Gene therapy methods in cardiovascular diseases. Meth Enzymol 2002; 346: 311-320.
3. Hiltunen MO et al. Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods. FASEB J 2000; 14: 2230-2236.
4. Nicklin SA et al. Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. Circulation 2000; 102: 231-237.
5. Hall FL et al. Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor. Hum Gene Ther 2000; 11: 983-993.
6. Ribault S et al. Chimeric smooth muscle-specific enhancer/promoters: valuable tools for adenovirus-mediated cardiovascular gene therapy. Circ Res 2001; 88: 468-475.
7. Gordon EM et al. Lesion-targeted injectable vectors for vascular restenosis. Hum Gene Ther 2001; 12: 1277-1287.
8. Nicklin SA et al. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther 2001; 4: 174-181.
9. Nicklin SA et al. Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Mol Ther 2001; 4: 534-542.
10. Turunen MP et al. Peptide re-targeted adenovirus encoding tissue inhibitor of metalloproteinase-1 decreases restenosis after intravascular gene transfer. Mol Ther 2002 (in press).
11. Ylä-Herttuala S, Martin JF. Cardiovascular gene therapy. Lancet 2000; 355: 213-222.
12. Kibbe MR et al. Optimizing cardiovascular gene therapy: increased vascular gene transfer with modified adenoviral vectors. Arch Surg 2000; 135: 191-197.
13. Hay CM et al. Enhanced gene transfer to rabbit jugular veins by an adenovirus containing a cyclic RGD motif in the HI loop of the fiber knob. J Vasc Res 2001; 38: 315-323.
14. Mizuguchi H et al. CAR- or alhav integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. Gene Therapy 2002; 9: 769-776.
15. Eslami MH et al. Gene delivery to in situ veins: differential effects of adenovirus and adeno-associated viral vectors. J Vasc Surg 2000; 31: 1149-1159.
16. Skelly CL et al. Prevention of restenosis by a herpes simplex virus mutant capable of controlled long-term expression in vascular tissue in vivo. Gene Therapy 2001; 8: 1840-1846.
17. Roks AJ et al. Recombinant Semliki Forest virus as a vector system for fast and selective in vivo gene delivery into balloon-injured rat aorta. Gene Therapy 2002; 9: 95-101.
18. Airenne KJ et al. Baculovirus-mediated periadventitial gene transfer to rabbit carotid artery. Gene Therapy 2000; 7: 1499-1504.
19. Amabile PG et al. High-efficiency endovascular gene delivery via therapeutic ultrasound. J Am Coll Cardiol 2001; 37: 1975-1980.
20. Klugherz BD et al. Gene delivery from a DNA controlled-release stent in porcine coronary arteries. Nat Biotechnol 2000; 18: 1181-1184.
21. Klugherz BD et al. Gene delivery to pig coronary arteries from stents carrying antibody-tethered adenovirus. Hum Gene Ther 2002; 13: 443-454.
22. Panetta CJ et al. A tissue-engineered stent for cell-based vascular gene transfer. Hum Gene Ther 2002; 13: 433-441.
23. Brasen JH et al. Angiogenesis, vascular endothelial growth factor and platelet-derived growth factor-BB expression, iron deposition, and oxidation-specific epitopes in stented human coronary arteries. Arterioscler Thromb Vasc Biol 2001; 21: 1720-1726.
24. Yoshimura S et al. Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factor-kappaB binding site as a novel molecular strategy. Gene Therapy 2001; 8: 1635-1642.
25. Nakamura T et al. Molecular strategy using cis-element 'decoy' of E2F binding site inhibits neointimal formation in porcine balloon-injured coronary artery model. Gene Therapy 2002; 9: 488-494.
26. Kipshidze NN et al. Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model. J Am Coll Cardiol 2002; 39: 1686-1691.
27. Maillard L et al. Effect of percutaneous adenovirus-mediated Gax gene delivery to the arterial wall in double-injured atheromatous stented rabbit iliac arteries. Gene Therapy 2000; 7: 1353-1361.
28. Leppanen O et al. Intimal hyperplasia recurs after removal of PDGF-AB and -BB inhibition in the rat carotid artery injury model. Arterioscler Thromb Vasc Biol 2000; 20: E89-E95.
29. Ding H et al. Adenovirus-mediated expression of a truncated PDGFbeta receptor inhibits thrombosis and neointima formation in an avian arterial injury model. Thromb Haemost 2001; 86: 914-922.
30. Hiltunen MO et al. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation 2000; 102: 2262-2268.
31. Rutanen J et al. EGD-D is abundantly expressed in human arteries and gene transfer of VEGF-DΔNΔC reduces neointima formation in balloon-denuded rabbit aorta. Mol Ther 2002; 5: S354-S355.
32. Hayashi K et al. In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model. Gene Therapy 2000; 7: 1664-1671.
33. Laukkanen MO. Adenovirus-mediated extracellular superoxide dismutase gene therapy reduces neointima formation in balloon denuded rabbit aorta. Circulation 2002 (in press).
34. Quarck R et al. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001, 103: 2495-2500.
35. Zoldhelyi P et al. Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries. Proc Natl Acad Sci USA 2001; 98: 4078-4083.
36. Golino P et al. Expression of exogenous tissue factor pathway inhibitor in vivo suppresses thrombus formation in injured rabbit carotid arteries. J Am Coll Cardiol 2001; 38: 569-576.
37. Atsuchi N et al. Combination of a brief irrigation with tissue factor pathway inhibitor (TFPI) and adenovirus-mediated local TFPI gene transfer additively reduces neointima formation in balloon-injured rabbit carotid arteries. Circulation 2001; 103: 570-575.
38. Puhakka HP et al. eptide re-targeted adenoviral combination gene therapy coding TIMP-1 and VEGF-C has a long term effect on reducing restenosis. Mol Ther 2002; 5: S163.
39. Leppänen O et al. Combination of VEGF-C gene transfer and treatment with the PDGF receptor kinase inhibitor STI571 leads to persistent reduction in neointima formation in balloon-denuded rabbit aorta. J Am Coll Cardiol 2002; 39: 872.
40. George SJ et al. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated over-expression of tissue inhibitor of metalloproteinase-3. Circulation 2000; 101: 296-304.
41. Ehsan A et al. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg 2001; 121: 714-721.
42. Ohno N et al. Accelerated reendothelialization with suppressed thrombogenic property and neointimal hyperplasia of rabbit jugular vein grafts by adenovirus-mediated gene transfer of C-type natriuretic peptide. Circulation 2002; 105: 1623-1626.
43. Grube, E. E2F Decoy-gene therapy in bypass grafts. American Heart Association 2001 Meeting (Plenary Session: Late Breaking Clinical Trials). 2001.
44. Makinen K et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002; 6: 127-133.
45. Kutryk MJ et al. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis. Results of the randomized investigation by the thoraxcenter of antisense dna using local delivery and ivus after coronary stenting (ITALICS) trial. J Am Coll Cardiol 2002; 39: 281-287.
46. Tsui LV et al. p27-p16 fusion gene inhibits angioplasty-induced neointimal hyperplasia and coronary artery occlusion. Circ Res 2001; 89: 323-328.
47. Wu CH et al. Inhibition of neointimal formation in porcine coronary artery by a Ras mutant. J Surg Res 2001; 99: 100-106.
48. Condorelli G et al. Mutated p21/WAF/CIP transgene overexpression reduces smooth muscle cell proliferation, macrophage deposition, oxidation-sensitive mechanisms, and restenosis in hypercholesterolemic apolipoprotein E knockout mice. FASEB J 2001; 15: 2162-2170.
49. Ascher E et al. Effect of p53 gene therapy combined with CTLA4Ig selective immunosuppression on prolonged neointima formation reduction in a rat model. Ann Vasc Surg 2000; 14: 385-392.
50. Luo Z et al. Enhancement of Fas ligand-induced inhibition of neointimal formation in rabbit femoral and iliac arteries by coexpression of p35. Hum Gene Ther 2001; 12: 2191-2202.
51. Larson RA et al. Adenoviral-mediated uteroglobin gene transfer inhibits neointimal hyperplasia after balloon injury in the rat carotid artery. J Vasc Surg 2000; 32: 1111-1117.
52. Yamamoto K et al. Ribozyme oligonucleotides against transforming growth factor-beta inhibited neointimal formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular disease. Circulation 2000; 102: 1308-1314.
53. Eto Y et al. Gene transfer of dominant negative Rho kinase suppresses neointimal formation after balloon injury in pigs. Am J Physiol Heart Circ Physiol 2000; 278: H1744-H1750.
54. Varenne O et al. Percutaneous gene therapy using recombinant adenoviruses encoding human herpes simplex virus thymidine kinase, human PAI-1, and human NOS3 in balloon-injured porcine coronary arteries. Hum Gene Ther 2000; 11: 1329-1339.
55. Lamfers ML et al. In vivo suppression of restenosis in balloon-injured rat carotid artery by adenovirus-mediated gene transfer of the cell surface-directed plasmin inhibitor ATF.BPTI. Gene Therapy 2001; 8: 534-541.
56. Izumi Y et al. Gene transfer of dominant-negative mutants of extracellular signal-regulated kinase and c-Jun NH2-terminal kinase prevents neointimal formation in balloon-injured rat artery. Circ Res 2001; 88: 1120-1126.